assertion (references)

Nanopublication	Part	Subject	Predicate	Object	Published By	Published On
http://purl.org/np/RAQpp12qzkzqBMsz2q-vYLAf5nTBPkT9aS4OjjAwA-E3U RAQpp12qzk	links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance	assertion	http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo	https://orcid.org/0000-0002-3668-2627 Elif Ozkan	Elif Ozkan	2022-10-13T13:46:07.779Z
http://purl.org/np/RAQpp12qzkzqBMsz2q-vYLAf5nTBPkT9aS4OjjAwA-E3U RAQpp12qzk	links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance	assertion	http://www.w3.org/ns/prov#generatedAtTime generatedAtTime	2022-10-13T13:46:07.779203	Elif Ozkan	2022-10-13T13:46:07.779Z
http://purl.org/np/RAQpp12qzkzqBMsz2q-vYLAf5nTBPkT9aS4OjjAwA-E3U RAQpp12qzk	links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance	assertion	http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom	Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral testing. This combination regimen is also used for post-exposure prophylaxis of COVID-2019 in unvaccinated or immunocompromised adults.	Elif Ozkan	2022-10-13T13:46:07.779Z